Sax PE, et al. — This study compared first-line HIV-1 treatment with bictegravir in combination with the nucleotide reverse transcriptase inhibitors (NRTIs) combination emtricitabine and tenofovir alafenamide to dolutegravir in combination with emtricitabine and tenofovir alafenamide. Reseachers concluded that HIV virological suppression was not inferior with the bictegravir regimen compared with the dolutegravir regimen as initial therapy in adults at 48 weeks and was safe and well-tolerated. No resistance was noted with either regimen.